Scientific Development Scientist, SynBio - AMER EAST
Twist Bioscience- Full Time
- Junior (1 to 2 years)
The ideal candidate should possess a Ph.D. in immunology, oncology, or a related field, along with 3-5 years of experience in cell therapy, immunology, self-replicating virology, or autoimmune disease. Extensive knowledge of in vivo CAR-T and deep understanding of AID is required, alongside experience with cellular and immune cell-based analytics, assay development including multi-parameter flow-cytometry, and immunogenicity assays. Experience with lentivirus engineering, packaging, and characterization assays, as well as in vivo tissue/cell-specific gene delivery in animal models, is considered a plus, and genome editing experience is also beneficial.
As a Senior Scientist of Immunology, the candidate will isolate immune cells, activate and expand them using flow cytometry, perform functional assays such as cytotoxicity and cytokine secretion, engineer virus genomes, package and characterize engineered virus particles, develop and optimize immunoassays to detect host immune response, conduct functional analysis of transduced cells, deliver experiment results meeting timelines, prepare reports and presentations, maintain laboratory documentation, ensure compliance with GLP and EHS protocols, and present results in team meetings.
Develops and commercializes cell therapies
Legend Biotech develops and commercializes cell therapies aimed at treating serious diseases, particularly cancers like hematological malignancies and solid tumors. Their approach is technology agnostic, allowing them to explore various methods to find effective treatments. The company operates in the personalized medicine sector, focusing on discovering, developing, and bringing new therapies to market. They generate revenue through licensing and selling their therapies, including CAR-T therapies, which involve modifying a patient's cells to combat cancer. Legend Biotech emphasizes transparency with investors, regularly updating them on financial results and business developments.